远大医药丙酸氟替卡松鼻喷雾剂获批上市
4月22日，远大医药（00512）发布公告，本集团开发的用于治疗过敏性鼻炎的丙酸氟替卡松鼻喷雾剂近日获得中国国家药品监督管理局颁发的药品注册证书，成为中国首仿上市产品，并已纳入国家医保目录和国家基本用药目录。
根据相关流行病学调查，中国成人过敏性鼻炎患病率约为17.6%，患者群体接近2.5亿，显示出巨大的市场需求。鼻用制剂市场规模在2023年接近35亿元，主要产品的合计市场规模约为23亿元，占整个市场的65%。公司首仿的布地奈德鼻喷雾剂上市后销售显著增长，证明了国内产品替代市场的潜力。此次丙酸氟替卡松鼻喷雾剂的上市有望进一步打破原研产品的市场垄断，公司还在积极推进糠酸莫米松鼻喷雾剂的注册工作。
（文章来源：财中社）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Most Discussed
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10